CelcuityFRA:7VR -1.14%11 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Celcuity ranks worse than 142450% on this metric.
The historical rank and industry rank for Celcuity's Days Payable or its related term are showing as below:
FRA:7VR's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56 * Ranked among companies with meaningful Days Payable only.
Celcuity's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Celcuity Days Payable Related Terms
Celcuity Days Payable Historical Data
* Premium members only.
The historical data trend for Celcuity's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VR vs ERAS, TNGX, DNTH: Days Payable Comparison
For the Biotechnology subindustry, Celcuity's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celcuity Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celcuity's Days Payable distribution charts can be found below:
* The bar in red indicates where Celcuity's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Celcuity's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celcuity (FRA:7VR) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #999999 out of 702 companies in the Biotechnology industry.
Is Celcuity's Days Payable too high?
Celcuity's current Days Payable is 0.00. Based on the distribution chart, Celcuity ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celcuity has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Days Payable compare to ERAS and TNGX?
According to the Biotechnology industry distribution chart, Celcuity ranks #999999 out of 702 companies for Days Payable. This places Celcuity in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celcuity and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celcuity's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Days Payable of 0.00. The current Days Payable is 0.00. Celcuity's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
11GF Score
Get the complete analysis for FRA:7VR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VR has been successfully added to your 
